Vaginal micronized progesterone versus the levonorgestrel‐releasing intrauterine system for treatment of non‐atypical endometrial hyperplasia: A randomized controlled trial.
- Resource Type
- Article
- Authors
- Gezer, Şener; Köle, Emre; Aksoy, Lale
- Source
- International Journal of Gynecology & Obstetrics. May2023, Vol. 161 Issue 2, p661-666. 6p.
- Subject
- *LEVONORGESTREL intrauterine contraceptives
*ENDOMETRIAL hyperplasia
*RANDOMIZED controlled trials
*PROGESTERONE
- Language
- ISSN
- 0020-7292
Objective: To compare the efficiency of vaginal micronized progesterone (VMP) with the levonorgestrel‐releasing intrauterine system (LNG‐IUS) in patients with non‐atypical endometrial hyperplasia. A validated Menorrhagia Impact Questionnaire (MIQ) was used to assess the quality of life before and after the procedure. Methods: In this prospective trial, 144 women were randomly assigned to the VMP or LNG‐IUS group. The primary endpoint was the regression rate of endometrial hyperplasia after 3 months of treatment. The protocol was approved by the institutional ethics committee and registered at ClinicalTrials.gov (NCT03992937). Results: In all, 138 patients were analyzed. The regression rate was not significantly different between the groups (95.8% with LNG‐IUS vs. 90.8% with VMP; P = 0.194). Differences between pre‐ and post‐treatment MIQ scores were similar, except that better scores were obtained in the VMP group for the perception of the amount of blood loss (P = 0.035). Conclusion: VMP is as effective as the LNG‐IUS as a local treatment of endometrial hyperplasia without atypia. Trial registration: https://clinicaltrials.gov/ct2/show/NCT03992937. Synopsis: Vaginal micronized progesterone is as effective as the levonorgestrel‐releasing intrauterine system as a local treatment of endometrial hyperplasia without atypia. [ABSTRACT FROM AUTHOR]